In addition, a combination of PLX4720, a BRAFV600E inhibitor and anti-PD-L1/PD-1 antibody in a preclinical model of ATC, reduced the tumor growth, and increased in tumor CD8+ cytotoxic T cells, FoxP3+ Tregs, and NK cells, thus demonstrating an induction of the immunosuppressive tumor microenvironment. This evidence concerns the gene CD8A and neoplasm.